BackRHÖN-KLINIKUM Aktiengesellschaft Overview

RHÖN-KLINIKUM Aktiengesellschaft EBIT

Latest ebit for RKAGY: $58M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$13.62M
↑ 14.87% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$57.59M
↑ 6.45% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

RHÖN-KLINIKUM Aktiengesellschaft (RKAGY) FAQ

As of the most recent data (September 2026), RKAGY shows a EBIT of $58M. That compares with $54M in the prior-year period — up 6.4% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, RKAGY's EBIT is now $58M (was $54M) — a 6.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether RHÖN-KLINIKUM Aktiengesellschaft is outperforming or lagging.

The its sector sector average EBIT is about $2.4T. RHÖN-KLINIKUM Aktiengesellschaft is at $58M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how RKAGY stacks up against individual peers as well.

Tracking RKAGY's ebit over time shows whether RHÖN-KLINIKUM Aktiengesellschaft is scaling, shrinking, or reshaping that part of the business. The current reading is $58M That compares with $54M in the prior-year period — up 6.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has RHÖN-KLINIKUM Aktiengesellschaft's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $58M) with ownership activity and broader fundamentals.